Literature DB >> 15601382

No correlation of depression and anxiety to plasma estrogen and progesterone levels in patients with premenstrual dysphoric disorder.

Cheng-Cheng Hsiao1, Chia-Yih Liu, Mei-Chun Hsiao.   

Abstract

A number of studies have demonstrated the correlation of depression and anxiety to estrogen and progesterone in premenstrual dysphoric disorder (PMDD), but the findings are still controversial. The purpose of this study was to determine the correlation of depression and anxiety to estrogen and progesterone concentrations in blood plasma in Taiwanese women with PMDD. A total of 43 women who met the 4th edition of the Diagnostic and Statistical Manual diagnostic criteria for PMDD were enrolled in this study. Blood samples were obtained for determination of estrogen and progesterone levels, and depression and anxiety ratings were summed for each subject during one menstrual cycle to obtain a premenstrual result (2-6 days before menses) and a postmenstrual result (menstrual cycle days 7-11). Anxiety was assessed using the 14-item Hamilton Anxiety Scale-A and was also assessed by the patients themselves using the Trait Anxiety Inventory. Depression was rated using the 21-item Hamilton Anxiety Scale-D. Calculations were made to determine the relationships between hormonal changes and mood changes. There were no statistically significant correlations between depression or anxiety ratings and estrogen or progesterone concentrations.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15601382     DOI: 10.1111/j.1440-1819.2004.01308.x

Source DB:  PubMed          Journal:  Psychiatry Clin Neurosci        ISSN: 1323-1316            Impact factor:   5.188


  8 in total

Review 1.  Progesterone, reproduction, and psychiatric illness.

Authors:  Lindsay R Standeven; Katherine O McEvoy; Lauren M Osborne
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2020-06-18       Impact factor: 5.237

2.  Neuropsychopharmacological properties of neuroactive steroids in depression and anxiety disorders.

Authors:  Daniela Eser; Cornelius Schüle; Elena Romeo; Thomas C Baghai; Flavia di Michele; Augusto Pasini; Peter Zwanzger; Frank Padberg; Rainer Rupprecht
Journal:  Psychopharmacology (Berl)       Date:  2005-10-25       Impact factor: 4.530

3.  Steroid withdrawal in the mouse results in anxiogenic effects of 3alpha,5beta-THP: a possible model of premenstrual dysphoric disorder.

Authors:  Sheryl S Smith; Yevgeniy Ruderman; Cheryl Frye; Gregg Homanics; Maoli Yuan
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

4.  Differences in free estradiol and sex hormone-binding globulin in women with and without premenstrual dysphoric disorder.

Authors:  Susan Thys-Jacobs; Don McMahon; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2007-10-23       Impact factor: 5.958

5.  Paeonol at Certain Doses Alleviates Aggressive and Anxiety-Like Behaviours in Two Premenstrual Dysphoric Disorder Rat Models.

Authors:  Hao Zhang; Xiwen Geng; Zifa Li; Yaqiong Li; Kaiyong Xu; Hongyun Wu; Jinlu Xie; Peng Sun; Sheng Wei; Mingqi Qiao
Journal:  Front Psychiatry       Date:  2020-04-15       Impact factor: 4.157

6.  Lowered Plasma Steady-State Levels of Progesterone Combined With Declining Progesterone Levels During the Luteal Phase Predict Peri-Menstrual Syndrome and Its Major Subdomains.

Authors:  Chutima Roomruangwong; André F Carvalho; Frank Comhaire; Michael Maes
Journal:  Front Psychol       Date:  2019-10-30

7.  Association between Generalized Anxiety Disorder and Premenstrual Dysphoric Disorder in a Diagnostic Interviewing Study.

Authors:  Ju-Yu Yen; Pai-Cheng Lin; Mei-Feng Huang; Wei-Po Chou; Cheng-Yu Long; Chih-Hung Ko
Journal:  Int J Environ Res Public Health       Date:  2020-02-05       Impact factor: 3.390

8.  Early- and Late-Luteal-Phase Estrogen and Progesterone Levels of Women with Premenstrual Dysphoric Disorder.

Authors:  Ju-Yu Yen; Huang-Chi Lin; Pai-Cheng Lin; Tai-Ling Liu; Cheng-Yu Long; Chih-Hung Ko
Journal:  Int J Environ Res Public Health       Date:  2019-11-07       Impact factor: 3.390

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.